ABSTRACT
OBJECTIVES: Acquired hemophilia A (AHA) is a rare, but potentially life-threatening, bleeding disorder caused by an autoantibody against factor VIII that interferes with its coagulant function. METHODS: We performed a narrative review focusing on the diagnostic aspects of AHA and on the current treatment strategies with particular regard to new data and therapeutic developments. RESULTS: The management of this severe hemorrhagic disorder is based on the control of bleeding with the use of bypassing agents and on the utilization of a variety of immunosuppressant agents with the goal of eliminating the autoantibody permanently. CONCLUSION: The optimal management of AHA should be multidisciplinary and requires a close collaboration between physicians from various specialties.
Subject(s)
Hemophilia A/diagnosis , Hemophilia A/therapy , Algorithms , Autoantibodies/immunology , Blood Coagulation Tests , Disease Management , Factor VIII/immunology , Hemophilia A/etiology , Hemorrhage/etiology , Hemorrhage/therapy , Hemostatics/therapeutic use , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunosuppressive Agents/therapeutic useSubject(s)
Blast Crisis/genetics , Chromosomes, Human, Pair 20/genetics , Chromosomes, Human, Pair 21/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Translocation, Genetic/genetics , Blast Crisis/pathology , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Male , Middle AgedABSTRACT
PURPOSE: A phase II dose-escalation trial was conducted to ascertain low-dose thalidomide safety and response in patients with advanced myelofibrosis with myeloid metaplasia (MMM). PATIENTS AND METHODS: Thalidomide was administered together with current therapy to 63 patients, starting at 50 mg daily and increasing to 400 mg as tolerated. RESULTS: Half of the patients sustained daily doses more than 100 mg and the drop-out rate was 51% at 6 months: the drop-out rate was lower in patients with high baseline fatigue score. At efficacy analysis, anemia was ameliorated in 22% of the patients and transfusions were eliminated in 39% of transfusion-dependent patients. Platelet count increased by 50 x 10(9)/L or more in 22% of patients with an initial count lower than 100 x 10(9)/L. Splenomegaly decreased by more than 50% of the initial size in 19% of patients. Reduction of an overall disease severity score occurred in 31% of patients and was associated with a significant reduction of fatigue. Disease severity amelioration was independently predicted by a high baseline myeloproliferative index (ie, large splenomegaly, thrombocytosis, or leukocytosis). CONCLUSION: Low-dose thalidomide displays an acceptable toxicity profile and provides an objective and subjective advantage to a relevant portion of MMM patients.
Subject(s)
Immunosuppressive Agents/administration & dosage , Leukopenia/prevention & control , Primary Myelofibrosis/drug therapy , Splenomegaly/prevention & control , Thalidomide/administration & dosage , Thrombocytopenia/prevention & control , Adolescent , Adult , Aged , Aged, 80 and over , Anemia/prevention & control , Female , Humans , Immunosuppressive Agents/adverse effects , Male , Middle Aged , Platelet Count , Primary Myelofibrosis/pathology , Safety , Severity of Illness Index , Thalidomide/adverse effects , Treatment OutcomeABSTRACT
Emergence of additional cytogenetic clones in chronic myelocytic leukemia (CML) patients who become Philadelphia chromosome-negative (Ph-) after alpha-interferon therapy (or more recently with imatinib mesylate) have been described. We report here a case of a novel t(6;7)(p21;q23) that developed in a CML patient in complete cytogenetic remission during imatinib therapy. In this case, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction showed a normal pattern for BCR and ABL genes, suggesting that a different and unrelated clone developed after the disappearance of the Ph chromosome.
Subject(s)
Chromosomes, Human, Pair 6 , Chromosomes, Human, Pair 7 , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Translocation, Genetic , Aged , Antineoplastic Agents/pharmacology , Benzamides , Humans , Imatinib Mesylate , In Situ Hybridization, Fluorescence , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Male , Piperazines/pharmacology , Pyrimidines/pharmacology , Remission InductionSubject(s)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Translocation, Genetic , Adult , Aged , Antineoplastic Agents/therapeutic use , Benzamides , Chromosomes, Human, Pair 6 , Chromosomes, Human, Pair 7 , Female , Humans , Imatinib Mesylate , In Situ Hybridization, Fluorescence , Male , Middle Aged , Remission InductionSubject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, Non-Hodgkin/drug therapy , Vidarabine/analogs & derivatives , Vidarabine/administration & dosage , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/toxicity , Female , Humans , Lymphoma, Non-Hodgkin/complications , Male , Treatment Outcome , Vidarabine/toxicityABSTRACT
BACKGROUND AND OBJECTIVES: Overexpression of P-glycoprotein (PGP), a multidrug-related (MDR) protein, is one of the most important factors responsible for reduced drug sensitivity in acute myeloid leukemia (AML). Recently, we demonstrated that the presence of CD56 antigen, an isoform of the neural adhesion molecule, in AML cells is a negative independent prognostic factor for the achievement of complete remission (CR) and correlates with shorter survival. Since in our previous report we observed a more frequent PGP expression in CD56+ patients, we hypothesized that the reduced response to chemotherapy in this group of patients was due to increased PGP-mediated drug efflux. To confirm this hypothesis in this study PGP and CD56 expression on AML cells was correlated with other clinical and biological features and treatment response. DESIGN AND METHODS: Immunophenotypic analysis, including evaluation of CD56 and PGP expression, was performed using multiparameter flow cytometry on fresh and/or cryopreserved blast cells, obtained after informed consent, from bone marrow and/or peripheral blood of 143 consecutive newly diagnosed AML cases at the time of diagnosis. Samples expressing CD56 in at least 15% or more cells were considered as positive (CD56+). PGP expression was expressed as a mean fluorescence index (MFI) i.e. as the ratio of sample mean fluorescence channel and the isotypic control mean fluorescence channel. RESULTS: Overall results showed that 67/143 cases were PGP-/CD56-, 23/143 were PGP+ /CD56+, 40/143 were PGP+/CD56- and the remaining 13/143 were PGP-/CD56+. CD56+ and PGP+ on AML cells significantly reduced the CR rate (83% in the PGP-/CD56- group vs 60% in the PGP-/CD56+ group, 46% in the PGP+/CD56- group and 58% in the PGP+/CD56+ group, p = 0.002). In addition we observed a significantly higher proportion of total failures in patients expressing PGP or CD56 compared to in the group not expressing either (73% vs 27%, respectively; p = 0.0001). CD56 and PGP overexpression influenced the overall survival: in fact, the median survival of CD56+ and PGP+ patients ranged from 10 to 23 months, while the actuarial survival of CD56-/PGP- patients at 5 years is 52% (p = 0.023). INTERPRETATION AND CONCLUSIONS: Our data underline the independent negative prognostic role of PGP and CD56 expression in acute myeloid leukemia. Since the mechanism by which CD56 reduces drug sensitivity is still unknown, further investigations are required.